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Background: MicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose
deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in
human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabetes,
pulmonary disease, colorectal cancer, and gastric cancer among others; however, defining a plasma miRNA
signature in acute myeloblastic leukemia (AML) that could serve as a biomarker for diagnosis or in the follow-up
has not been done yet.
Methods: TaqMan miRNA microarray was performed to identify deregulated miRNAs in the plasma of AML
patients. Quantitative real-time RT-PCR was used to validate the results. Receiver-operator characteristic (ROC) curve
analysis was conducted to evaluate the diagnostic accuracy of the highly and significantly identified deregulated
miRNA(s) as potential candidate biomarker(s).
Results: The plasma expression level of let-7d, miR-150, miR-339, and miR-342 was down-regulated whilst that of
let-7b, and miR-523 was up-regulated in the AML group at diagnosis compared to healthy controls. ROC curve
analyses revealed an AUC (the areas under the ROC curve) of 0.835 (95% CI: 0.7119– 0.9581; P<0.0001) and 0.8125
(95% CI: 0.6796–0.9454; P=0.0005) for miR-150, and miR-342 respectively. Combined ROC analyses using these 2
miRNAs revealed an elevated AUC of 0.86 (95% CI: 0.7819–0.94; P<0.0001) indicating the additive effect in the
diagnostic value of these 2 miRNAs. QRT-PCR results showed that the expression level of these two miRs in
complete remission AML patients resembled that of healthy controls.
Conclusions: Our findings indicated that plasma miR-150 and miR-342 are novel important promising biomarkers
in the diagnosis of AML. These novel and promising markers warrant validation in larger prospective studies.
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Acute myeloid leukemia (AML) is a clonal disorder caused
by malignant transformation of a bone marrow-derived pro-
genitor cell, which demonstrates an enhanced proliferation
as well as aberrant differentiation resulting in hematopoietic
insufficiency (i.e. granulocytopenia, thrombocytopenia or an-
aemia) [1,2]. AML is the most common type of acute* Correspondence: pmartiat@ulb.ac.be
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distribution, and reproduction in any mediumleukemia occurring in adults, with approximately 11,900
individuals diagnosed annually in the United States only [3].
Adults over age 60 comprise more than two-thirds of this
group [2], with a median age of onset of about 65 [3]. The in-
cidence of AML rises significantly with age, with 4 cases per
100,000 people annually in the sixth decade of life, to over 20
cases per 100,000 in the ninth decade of life [4]. An increased
incidence of AML is seen in patients with disorders asso-
ciated with excessive chromatin fragility such as Bloom
syndrome, Fanconi anemia, Kostmann syndrome, Wiskott-
Aldrich syndrome or ataxia telangiectasia syndrome. Otherentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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variants), and Patau (trisomy 13), have also been associated
with a higher incidence of AML [5-8]. In fact, AML patients
in remission frequently relapse due to the addition of new
mutations [9].
In general, adults with AML show a variety of symptoms
including fatigue, bruising or bleeding, fever, and in-
fection, reflecting a state of bone marrow failure [10].
Physical findings other than bleeding and infection may
include organomegaly, lymphadenopathy, sternal tender-
ness, retinal hemorrhages, and infiltration of gingivae,
skin, soft tissues, or meninges (more common with mono-
cytic variants M4 or M5) [10]. The diagnosis of AML is
often demonstrated by an increased number of myelo-
blasts in the bone marrow or peripheral blood. According
to the WHO criteria, acute leukemia is diagnosed when a
200-cell differential reveals the presence of 20% or more
myeloblasts in a marrow aspirate or in blood [11].
MicroRNAs (miRNAs) are small (19-22-nt) single-
stranded noncoding RNA molecules that are derived from
hairpin-structured precursors [12]. These microRNAs
function by directly binding to their potential target site in
the 30 untranslated region (30UTRs) of specific target
mRNA, leading to the repression of mRNA translation or
the degradation of target mRNAs. Small non-coding
RNAs were also recently implicated in control of DNA-
damage response [13]. Currently, there are 2042 mature
human miRNA sequences listed in the miRNA registry
(Sanger miRBase release 19; http://www.mirbase.org/).
Over recent years, many miRNAs have been investigated
in various human cancers [14,15]. The deregulation of
expression of microRNAs has been shown to contribute
to the multistep processes of carcinogenesis in human by
modification either of oncogenic or suppressor gene func-
tion [16,17]. Nowadays, microRNA expression patterns
are known to characterize the developmental origins of
tumors more effectively than mRNA expression signatures
and thus can be a useful tool for the diagnosis and prog-
nosis of human cancer [18]. The search for non-invasive
tools for the diagnosis and management of cancer that
can greatly reduce its worldwide health burden has long
been a goal of cancer research [19]. Recently, it has been
reported that microRNAs are circulating in serum/plasma
[20,21] and tumor-derived microRNAs such as miR-155,
miR-21, miR-15b, miR-16 and miR-24 have been detected
in the plasma and sera of tumor-bearing patients [22,23].
These circulating microRNAs can be considered as a new
class of effective biomarkers where their abundance profile
might reflect physiological and/or pathological conditions.
Accordingly, several subsequent studies have proven that
miRNAs can serve as potential biomarkers for various dis-
eases including cancer [20,24,25].
A previous report [26] had shown that down-regulation
of miR-92 is a novel marker for acute leukemia patients(AML, ALL). In our study, we investigated the profile of
circulating microRNAs in the plasma of acute myeloid
leukemia patients compared with healthy individuals. Our
results have revealed the presence of two microRNAs
(miR-150, miR-342) whose levels were very significantly
downregulated in the plasma of AML patients at diagnosis
compared to healthy controls. The combination of their
decrease is of utmost significance using ROC curve ana-
lysis. Investigation of the expression level of these two
microRNAs in complete remission (CR) AML patients by
qRT-PCR revealed a similar expression level as that of
healthy controls. Thus, besides miR-92, these two micro-
RNAs are novel candidate biomarkers of acute myeloid
leukemia and potential predictors of relapse.Methods
Patients
Patients used in this study had a newly diagnosed AML in
addition to being in complete remission as determined by
blood test. A total of 20 patients at the time of diagnosis
in addition to other 20 patients in complete remission
provided blood samples. Healthy subjects were collected
as negative controls. None of these controls had previ-
ously been diagnosed with any type of malignancy or
other benign disease. Informed consent, approved by the
Clinical Research Ethics Committee of Jules Bordet Insti-
tute, was obtained from each participant. Details of clinical
data are provided in Table 1.Plasma sampling and RNA extraction
At presentation, blood samples for miRNA detection were
collected in EDTA-K2 tubes and processed within 1 hour
of collection. Blood samples were centrifuged at 1,200 g
for 10 min at 4°C to spin down the blood cells, and the
supernatant was transferred into microcentrifuge tubes,
followed by a second centrifugation at 12,000 g for 10 min
at 4°C. The supernatant was transferred to RNase/DNase-
free tubes and stored at −80°C. Total RNA was isolated
from the plasma using a mirVana PARIS isolation kit
(Ambion, Austin, Texas) according to the manufacturer’s
instructions for plasma samples. Briefly, 400 μL of human
plasma was used to extract total RNA. Each sample was
eluted in 100 μL of RNAse-free water and was concen-
trated to a final volume of 20 μL by using Eppendorf Con-
centrator Plus 5301 (Eppendorf, Germany).
RNA sample concentration was quantified by Nano-
Drop ND-1000 (Nanodrop, USA). All RNA samples were
analyzed for miR-16 expression, a stable endogenous
reference miRNA, to assess an approximate yield of RNA
extraction and to ensure that comparable amounts of
starting material were used in each reverse transcription
reaction [22,28-31].
Table 1 Summary of clinical details of AML patients and
















The classification was done according to the French-American-British system
[27].
M0= Undifferentiated acute myeloblastic leukemia; M1= Acute myeloblastic
leukemia with minimal maturation; M2= Acute myeloblastic leukemia with
maturation; M3=Acute promyelocytic leukemia (APL); M4= Acute
myelomonocytic leukemia; M4E0=Acute myelomonocytic leukemia with
eosinophilia; M5= Acute monocytic leukemia; M6= Acute erythroid leukemia;
M7= Acute megakaryoblastic leukemia.
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In our study, a three-step procedure was performed to pro-
file the miRNAs in the plasma samples. First, for cDNA
synthesis from the miRNAs, 30 ng of total RNA was sub-
jected to RT (reverse transcription) using a TaqManW
microRNA Reverse Transcription Kit (#4366596; Applied
Biosystems) and Megaplex RT primers (Human Pool A,
#4399966; Applied Biosystems) following the manu-
facturer’s protocol, allowing simultaneous reverse transcrip-
tion of 380 mature human miRNAs to generate a miRNA
cDNA library corresponding to each plasma sample. RT
was performed on a Mastercycler Epgradient thermocycler
(Eppendorf) with the following cycling conditions: 40 cycles
at 16°C for 2 min, 42°C for 1 min and 50°C for 1 s followed
by a final step of 80°C for 5 min to inactivate reverse tran-
scriptase. Thereafter, to generate enough miRNA cDNA
template for the following real-time PCR, the cDNA librar-
ies were pre-amplified using Megaplex PreAmp primer
(Humam Pool A, #4399233; Applied Biosystems) and Pre-
Amp Master Mix (#4384266; AppliedBiosystems) following
the manufacturer’s instructions. The PreAmp primer pool
used here consisted of forward primers specific for each of
the 380 human miRNAs and a universal reverse primer.
The pre-amplification cycling conditions were as follows:
95°C for 10 min, 55°C for 2 min, 72°C for 2 min followed
by 12 cycles at 95°C for 30 s and 60°C for 4 min; the sam-
ples were then held at 99.9°C for 10 min. After the pream-
plification step, the products were diluted with RNase-freewater, combined with TaqMan gene expression Master Mix
and then loaded into TaqMan Human MicroRNA Array A
(#4398965; Applied Biosystems), which is a 384-well for-
matted plate and real-time PCR-based microfluidic card
with embedded TaqMan primers and probes in each well
for the 380 different mature human miRNAs; MiR-16 tran-
script was used as a normalization signal.
Real-time PCR was performed on an ABI PRISM
7900HT sequence detection system (Applied Biosystems)
with the following cycling conditions: 50°C for 2 min,
94.5°C for 10 min followed by 40 cycles at 95°C for 30 s
and 59.7°C for 1 min. The Ct (cycle threshold) was auto-
matically given by SDS 2.3 software (Applied Biosys-
tems) and is defined as the fractional cycle number at
which the fluorescence passes the fixed threshold of 0.2.
MiR-16 embedded in the TaqMan Human MicroRNA
Arrays was used as an endogenous control. The relative
expression levels of miRNAs were calculated using the
comparative ΔΔCt method as described previously
[32,33]. The fold changes in miRNAs were calculated by
the equation 2−ΔΔCt.
Taqman miRNA assay for individual miRNAs
Gene-specific reverse transcription was performed for
each miR using 10 ng of purified total RNA, 100 mM
dNTPs, 50 U MultiScribe reverse transcriptase, 20 U
RNase inhibitor, and 50 nM of gene-specific RT primer
samples using the TaqMan MicroRNA Reverse Transcrip-
tion kit (Applied Biosystems, Gent, Belgium). 15 μl reac-
tions were incubated for 30 min at 16°C, 30 min at 42°C,
and 5 min at 85°C to inactivate the reverse transcriptase.
Real time RT-PCR reactions (5 μl of RT product, 10 μl
TaqMan 2x Universal PCR master Mix, (Applied Biosys-
tems, Gent, Belgium), and 1 μl TaqMan MicroRNA Assay
Mix containing PCR primers and TaqMan probes) were
carried out on ABI Prism 7900HT Sequence Detection
System (Applied Biosystems, Gent, Belgium) at 95°C for
10 min followed by 40 cycles at 95°C for 15 s and 60°C for
1 min. The qRT-PCR reactions were performed in tripli-
cate, and the signal was collected at the end of every cycle.
Due to a lack of generally accepted standards, all qRT-
PCR data on single miRNA expression were analyzed as
unadjusted Ct values and standardized to miR-16. To va-
lidate miR-16 as a stable internal reference, its stability
during extraction was compared to that of synthetic cel-
miR-39, a miRNA of C. elegans that is not present in
humans. Twenty-five fmol of synthetic cel-miR-39 were
spiked in after adding the Denaturing Solution (provided
in the mirVana PARIS isolation kit) to the human plasma
samples to avoid degradation by endogenous RNases, and
the RNA was extracted. We measured the expression of
cel-miR-39, miR-16 and the validated differentially
expressed microRNAs in AML patients (diagnosis and
complete remission) and healthy controls. Afterwards, the
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and healthy controls was compared with miR-16 and cel-
miR-39 normalizers, respectively.
Statistical analysis
Data characterized by a normal distribution, determined
using Kolmogorov-Smirnov and Shapiro-Wilk normality
tests, were expressed as the mean and standard devi-
ation. Widely presented using the 2-ΔΔCt method, the
relative gene expression involves the gene of interest
data (Ct gene of interest) relative to an internal control
gene (Ct internal control gene), named delta Ct. The cal-
culated delta Ct ± SD for the patients was compared
with the delta Ct ± SD (SD stands for the standard de-
viation of the average delta Ct of the group) for the
healthy control group and tested for statistical signifi-
cance. Sensitivity, specificity, and the area under the
curve (AUC) for plasma microRNAs were determined
using Receiver Operator Characteristic (ROC) analysis.
Data were analyzed using Student’s t test. P-values <0.05
(*), <0.01 (**), and <0.001 (***) obtained using t-test were
considered statistically significant.
Results
Expression profiles of miRNAs in the plasma of AML
patients
RNA from twenty independent human AML patients and
healthy controls was first studied using the TLDA tech-
nique. We could identify several miRs that were statisti-
cally differentially expressed between AML and healthy
controls (Table 2). These microRNAs were further studied
to validate their differential expression by quantitative
Real Time PCR (qRT-PCR) and to investigate whether
anyone could be used as a candidate biomarker of AML
at the diagnosis.
Validation of candidate miRNAs
Differential miR expressions were validated by real-time
PCR in all samples. The change in candidate miRNAs for
the AML patients versus the healthy controls is shown inTable 2 Circulating plasma microRNA expression levels in
AML patients compared to healthy controls








Hsa-miR-523 5 0.022Figure 1. These data have been normalized by the expres-
sion level of miR-16, a widely used endogenous reference
miRNA that was also confirmed to be unchanged in our
experiments (TLDA cards). In addition, as cel-miR-39,
miR-16 is stable (Figure 2). Moreover, we compared the
difference in let-7b, let-7d, miR-150, miR-339, miR-342,
and miR-523 expression between AML patients and
healthy controls and obtained the same differences in their
expression regardless of whether cel-miR-39 or miR-16
was used as the normalizer (Figure 3), which further sup-
ports that miR-16 is a stable reference in this study.
The plasma expression level of let-7d, miR-150, miR-
339, and miR-342 was down-regulated whilst that of let-
7b, and miR-523 was up-regulated in the AML group
compared to healthy controls (Figure 1). To confirm that
the assay is reproducible, we also analyzed expression
levels in the plasma (second sampling) collected 1 h after
the first sampling of the plasma of three AML patients.
No significant difference in the levels of the above men-
tioned microRNAs was found between the first sampling
and the second sampling, which suggests that the assay is
reproducible (Figure 4).Diagnostic accuracy of plasma miR-150 and miR-342 in
AML
The ROC curve analysis was used to analyze the diag-
nostic accuracy of plasma miR-150 and miR-342. ROC
curve analyses revealed that both plasma miR-150 and
miR-342 could serve as valuable biomarkers for differentiat-
ing AML from controls with an AUC (the areas under the
ROC curve) of 0.835 (95% CI: 0.7119– 0.9581; P<0.0001)
and 0.8125 (95% CI: 0.6796–0.9454; P=0.0005), respectively
(Figures 5A and 5B).
At the cut-off value less than 2.79 for miR-150, the sen-
sitivity and the specificity were 80% and 70%, respectively.
At the cut-off value less than 1.146 for miR-342, the sensi-
tivity and the specificity were 70% and 85%, respectively.
Combination ROC analyses resulted in an increased AUC
of 0.86 (95% CI: 0.7819–0.94; P<0.0001) with 73.0% sensi-
tivity and 78% specificity indicating the additive effect in
the diagnostic value of these 2 miRNAs (Figure 5C).MiR-150 and miR-342 in CR AML patients showed an
expression level similar to that of healthy controls
ROC curve analyses revealed that plasma miR-150 and
miR-342 could serve as valuable biomarkers for differen-
tiating AML from controls. Thus, in order to confirm
that, we assessed the expression level of these two
microRNAs in CR AML patients, compared to AML
patients at diagnosis and healthy controls, using qRT-
PCR. Results showed that the plasma expression level of
miR-150 and miR-342 was similar to that of healthy con-






Figure 1 Relative expression levels of the six differentially expressed miRs. Six miRNAs are significantly differentially expressed in the
plasma of AML patients when compared to healthy controls (n=20). Data obtained by quantitative RT-PCR amplification of miRs are plotted.
p-values for each miRNA are shown. Boxes represent SE. Error bars represent SD; pooled data from five independent experiments. *p<0.05,
**p<0.01 AML patient versus Healthy controls (Student’s t-test).
Figure 2 miR-16 expression level is stable in both healthy
controls and AML patients. MiR-16 expression levels were assessed
by qRT-PCR and normalized by cel-miR-39. Shown are the relative
levels (mean ± S.D.) of five independent experiments performed on
all participants, each done in triplicate.
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microRNAs as additional novel biomarkers for AML.
Discussion
In this study, we identified several microRNAs in the
plasma of AML patients at diagnosis that were differen-
tially expressed compared to healthy controls. Among
these miRs, two were upregulated (Let-7b, miR-523) and
four were downregulated (let-7d, miR-150, miR-339, and
miR-342). Importantly, the expression level of these
microRNAs didn’t show any significant difference be-
tween the male and female donors implicated in this
study as revealed by student’s t- test statistical analysis.
The latter was performed based on the Kolmogorov-
Smirnov and Shapiro-Wilk normality analysis tests.
Among these microRNAs, miR-150, and miR-342 were
very significantly downregulated in the plasma of AML
patients as confirmed using ROC curve analysis (AUC of
0.835 and 0.8125) that revealed that miR-150, and miR-
342 were promising candidate biomarkers for AML at
diagnosis. These data suggest that microRNA expression
signature in plasma can serve as a valuable diagnostic
Figure 3 Relative plasma miR-150 and miR-342 expression levels normalized by cel-miR-39 and hsa-miR-16. MiR-150 (A, B) and miR-342
(C, D) expression levels were assessed by qRT-PCR and normalized by cel-miR-39 and hsa-miR-16 respectively in healthy controls and Acute
Myeloid Leukemia patients. Shown are the relative levels (mean ± S.D.) of five independent experiments performed on all participants, each done
in triplicate. Statistical significance was determined by Student’s t test and is denoted as follows: ** p < 0.01 versus healthy donors.
Figure 4 miR-150 and miR-342 expression levels do not vary between the first and second sampling. Plasma miR-150 and miR-342
expression levels in the first sampling and second sampling were assessed by qRT-PCR. The expression level of these two microRNAs was
normalized to miR-16. Shown are the relative levels (mean ± S.D.) of five independent experiments performed on all participants, each done
in triplicate.
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Figure 5 Receiver operating characteristics (ROC) curve analysis using plasma miR-150 and miR-342 for discriminating AML patients.
Plasma miR-150 yielded an AUC (the areas under the ROC curve) of 0.835 (95% CI: 0.7119– 0.9581; P<0.0001) with 80% sensitivity and 70%
specificity in discriminating AML (A), and plasma miR-342 yielded AUC of 0.8125 (95% CI: 0.6796–0.9454; P=0.0005) with 70% sensitivity and 85%
specificity (B) in discriminating AML. Elevated ROC analysis revealed an elevated AUC of 0.860 (95% CI: 0.7819–0.94; P<0.0001) with 73% sensitivity






















































































































Figure 6 miR-150 and miR-342 expression levels in Remission AML patients resembles that of healthy controls. Plasma miR-150 and
miR-342 expression levels in remission AML patients and healthy controls were assessed by qRT-PCR. The expression level of these two
microRNAs was normalized to miR-16. Shown are the relative levels (mean ± S.D.) of five independent experiments performed on all controls,
each done in triplicate. Statistical significance was determined by Student’s t test and is denoted as follows: ** p < 0.01 versus healthy donors.
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that respect, the rebound in CR AML patients of miR-
150 and miR-342 at the healthy controls’ levels is of par-
ticular significance in the perspective of their use as
diagnostic and prognostic factors. Recent studies have
revealed that miRNAs are potential diagnostic biomar-
kers and prognostic factors in cancers [34,35]. Mitchell
et al. [23] were the first to identify the presence of circu-
lating tumor-associated miRNAs in plasma and to show
that circulating microRNAs may have an important
value for cancer diagnosis. Another group [24] also
determined that circulating miRNA profiles in patients
with lung cancer, colorectal cancer (CRC), and diabetes
had a prognostic significance. Although the clinical sig-
nificance of these observations has not been elucidated
in detail, those findings demonstrated that circulating
miRNAs could be non-invasive diagnostic or prognostic
markers for cancer and in this case for AML. A recent
study [35] showed that miR-150 was downregulated in
sepsis, both in granulocytes and monocytes and inversely
correlated with the severity of the disease. Interestingly,
plasma levels of tumor necrosis factor alpha, interleu-
kin-10, and interleukin-18, which all have a complemen-
tary sequence to miR-150, were negatively correlated
with the plasma levels of miR-150. This could impact on
the immune system response to leukemia. On the other
hand, an important report [36] related to miR-342
demonstrated the importance of its decreased plasma
level in breast cancer, particularly in resistance to certain
agents.
From a technical point of view, normalization is a key
step for the accurate quantification of RNA levels with
qRT-PCR. In our study, miR-16 was used as an internal
control for plasma miRNA quantification as is the case
of other studies carried out on different tumors, includ-
ing CRC [25] breast cancer [37] ovarian cancer [38]
where miR-16 was present in plasma/serum at similar
levels across normal controls and patients. In addition to
the normalization of qRT-PCR data, appropriate control
is also a key issue for diagnostic studies. It is therefore
crucial to ensure that the control group is free of any
disease, even benign, which is the case in this study. Lar-
ger sample size may also be helpful to eliminate poten-
tial sampling error.
Exosomes are small (50–90 nm) membrane vesicles of
endocytic origin that are released into the extracellular
environment on fusion of multivesicular bodies (MVB)
with the plasma membrane [39]. Many cells including
reticulocytes [40], dendritic cells [41], B cells [42], T cells
[43], mast cells [44], epithelial cells [45] and tumor cells
[46] have the capacity to release exosomes. Exosomes’
content, notably microRNAs known to exist in a form
that is resistant to plasmatic RNase activity [23], can be
delivered to another cell and function in a new location[47]. These studies suggest that microRNAs are pack-
aged inside exosomes that are secreted from cells. Thus,
it might be possible that cancer cells specifically take in
the exosome that contains miR-150 and miR-342 and as
a result, miR-150 and miR-342 decrease in the plasma.
In the study quoted above [35], the authors deter-
mined that the level of miR-150 was independent from
the number of white blood cells (WBC), but decreased
both in these normal WBCs and in the plasma. However,
the mechanism was not elucidated. Thus, an alternative
explanation could be that leukemic process creates a de-
crease in the normal WBC compartment and conse-
quently in the plasma. This is of course purely
speculative, and further experiments should address the
mechanisms involved.
In summary, we have shown that the expression level
of miR-150 and miR-342 in plasma is associated with
diagnosis of AML in human. Present knowledge does
not involve circulating miR-150 and miR-342 as refer-
ences in other human cancers [48,49].Conclusions
In our study, we identified 8 miRNAs differentially
expressed between plasma of AML patients and healthy
controls by TLDA. Among those eight microRNAs,
seven were confimed by qRT-PCR; let-7b and miR-523
were upregulated whilst others were downregulated in-
cluding the two highly significant microRNAs, miR-150,
and miR-342. Combination of these miRs has diagnostic
value enabling identification of AML with the sensitivity
of 73%, specificity 78% and AUC = 0.86. The diagnostic
value of these two microRNAs was confirmed where the
expression level of these two microRNAs in AML
patients at remission resembled that of healthy controls.
Thus, we believe, that circulating miR-150 and −342 in
plamsa are novel biomarkers in AML.
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